Authored by Peter Navarro via The Epoch Times,
I fought Anthony Fauci across a White House table over the China travel ban, lockdowns, masks, hydroxychloroquine, vaccines, and boosters.
Yet one of the most damning pieces of evidence I have ever seen against the man did not surface until six years later, when Sen. Rand Paul (R-Ky.) released Fauci's private pandemic diary.
It is an entry dated Aug. 15, 2021. The Biden White House was preparing to roll out a broad COVID booster campaign. Behind closed doors, Fauci knew there was a problem.
The evidence was thin.
The case for boosting everybody was weak.
And the administration needed a message.
Here is what Fauci wrote:
"If we are too precise we will be called out because we cannot back it with data."
Read that again.
This was not Anthony Fauci struggling heroically with scientific uncertainty. This was the president's chief medical adviser admitting, in private, that the government could not support its public booster message with the data.
Worse, the decision was already moving ahead.
Fauci described himself and the White House medical team as trying to "fashion [a] coherent message to justify the announcement" that boosters would be offered broadly.
The policy came first. The justification came afterward.And Fauci knew exactly where the scientific weakness lay.
In the same diary entry, he identified the real question: Did everybody need another shot, or only the elderly and those with underlying conditions?
That was not some question raised later by "anti-vaxxers." Fauci himself was asking it privately before the universal campaign rolled forward.
Yet instead of insisting that the government stop, gather the evidence, and tell Americans precisely what was known and unknown, Fauci helped fashion the message.
His own words are devastating: precision was dangerous because precision could expose that the government "cannot back it with data."
Five weeks later, the government's own scientific advisers effectively vindicated the concern Fauci had privately recorded - but publicly ignored.
On Sept. 17, 2021, the FDA's outside advisory committee voted 16-2 against Pfizer's request to give a booster to everyone 16 and older.
Then, when the proposal was narrowed to older and high-risk Americans, the same committee overwhelmingly supported it.
Same experts. Same meeting. Same evidence.
No to everybody.
Yes to those most at risk.
That was precisely the distinction Fauci had privately identified.
So what did Fauci do when independent experts arrived publicly at essentially the same conclusion he had privately entertained?
He did not celebrate science working as intended.
His diary records that he was "disappointed."
When FDA officials moved toward the narrower authorization, Fauci called it "a major mistake."
That tells you what this story is really about.
It is not simply that Anthony Fauci got a medical question wrong. Scientists get things wrong.
It is that the answer Fauci's Medical Industrial Complex wanted had begun to outrank the evidence.
A recommendation says: Here is what we know. Here is what we do not know. Here are the risks and benefits. You and your physician decide.
A mandate says: Take the product or pay a price - perhaps your job, your military career, your education, or your ability to participate in ordinary life.
The second requires stronger evidence than the first.
During COVID, Washington repeatedly moved in the opposite - and authoritarian - direction.
The more coercive the policy became, the simpler the message became.
Age disappeared.
Comorbidities disappeared.
Natural immunity was pushed aside.
Known concerns such as myocarditis in younger men became inconvenient complications to a universal slogan. Miscarriage risk in the first trimester - mum, not Mom, was the word.
Everybody vaccinate.
Everybody boost.
That is not informed consent.
That is compliance.
My forthcoming book, "Why Fauci MUST Rot in Prison: His Diary. My Diary. Your Verdict," puts Fauci's private diary beside the public record and beside my own contemporaneous record from inside the first Trump White House.
Again and again, Private Tony knew things Public Tony did not tell you.Private Tony had doubts.
Public Tony had certainty.
Private Tony saw complications.
Public Tony sold slogans.
And when the evidence threatened the slogan, the problem became how to "fashion" the message.
That is why this story matters to the MAHA movement far beyond Anthony Fauci.
MAHA must break the machinery that allowed one government official, surrounded by an obedient medical establishment, Big Pharma, compliant media, and censorious technology companies, to convert unsettled science into government dogma.
Science requires dissent.
Medicine requires individual judgment.
Informed consent requires the whole truth.
And no government official should ever again be permitted to hide uncertainty from the people while privately worrying that telling them the precise truth would expose that he could not "back it with data."
Views expressed in this article are opinions of the author and do not necessarily reflect the views of The Epoch Times.
Tyler Durden Sun, 09/13/2026 - 15:00Coordinated calls by the top AI execs, including Dario Amodei, Sam Altman and even Elon Musk, to slow development of the technology are likely to weigh on chipmaker and supply-chain stocks in the near term, Bloomberg reports, but will probably have limited long-term impact as spending on computing infrastructure remains strong, market watchers say, at least until the bond market cracks and credits refuse to fund the ROIC-free black hole that is the AI capex tsunami.
Semiconductor makers and other artificial intelligence-linked stocks may bear the brunt of any initial selloff on Monday, while investors assess whether a more cautious approach to developing advanced models will crimp earnings. Real-time price trackers on Hyperliquid indicate that both OpenAi and Anthropic are already facing notable losses following the Dario memo. SK Hynix contracts also slumped early Sunday on Hyperliquid. By 2 p.m. in Singapore, the contracts were trading down roughly 2.5% for the day.
Source: 0xcarlisleStill, with demand for chips, energy and computing power continuing to outstrip supply, weakness will likely prove short-lived.
Calls for restraint have grown in the industry, with Anthropic Chief Executive Officer Dario Amodei saying Saturday that the company would introduce additional safeguards, including independent third-party evaluations, and urged the broader industry to slow the pace of development of their most advanced models. OpenAI CEO Sam Altman backed the proposal, while xAI’s Elon Musk said “Dario is right.”
At the same time, investors including Gary Tan, a portfolio manager at Allspring Global Investments in Singapore, are doubtful the latest developments will have long-lasting effects on the industry.
“It may cause some short-term pressure, but it’s unlikely to derail the longer-term AI trade,” Tan said. “AI development is still at a relatively early stage, and I’m not sure the rest of the ecosystem is willing to accept the current pecking order and slow down while the technology continues to evolve so rapidly.”
Concerns over the vast sums being poured into AI have weighed on technology stocks as investors question whether earnings can justify soaring infrastructure costs. The scrutiny has left high-valuation shares linked to the technology particularly vulnerable, with signs of increased spending or weaker returns triggering selloffs. Plunging token costs have emerged as an especially sore point, as frontier models are unlikely to ever be able to grow into their massive revenue forecasts unless Chinese open-source models are hindered, which many say is the ulterior motive behind the coordinated push by AI execs. And should the likes of Anthropic and OpenAi be unable to fund the trillions in committed capital, the entire AI bubble can burst, led by a collapse in bond prices as creditors end up with major haircuts.
As part of the aggressive repricing in AI economics, the Nasdaq has dropped more than 4% from the record notched in June, while a gauge of chip shares in the US has slumped 14% and Asian tech stocks have slid almost 8%. The S&P 500 and MSCI’s gauge of global shares have both edged up about 0.6% in the period.
Some investors argue that a slower pace of AI development could ultimately be positive for the industry by giving companies more time to extract returns from infrastructure already being built.
“The three CEOs agreeing to pace things does not really change the money being spent on chips, power and infrastructure. In fact, it extends the development timeline,” said Billy Leung, an investment strategist at Global X Management in Sydney. “If commercialization and adoption keep growing while the pace of new capability eases off a bit, that actually helps the shift from spending money to build things towards making money from what’s already built — e.g., monetization.”
Sentiment toward Asian tech firms was already being challenged as traders firmed bets of a Fed rate hike this week and an increase in global borrowing costs this month, threatening to crimp profits. Tech stock valuations may also come under more scrutiny because they assume not only strong demand but a relentless pace of model development, Charu Chanana, chief investment strategist at Saxo Markets in Singapore, said.
Still, the souring mood may prove to be short-lived with a push for safeguards leading to more investment in cybersecurity and AI monitoring tools, she said. Memory, networking, cooling and power equipment companies are likely to be protected by projects already in development, Chanana said.
“Demand for computing power and AI adoption does not disappear because additional safeguards are introduced,” she said. “For investors, responsible development may make the AI opportunity more durable, even if the pace of progress becomes slightly more measured.”
What she didn't say is that the projects in development will only be developed as long as the creditors behind trillions in upcoming debt don't stage a revolt which is highly likely if the collapse in token prices isn't halted.
Tyler Durden Sun, 09/13/2026 - 14:35